With the FDA run­ning out of funds, health­care groups warn that the drug ap­proval process will soon be de­railed

The longest ever US gov­ern­ment shut­down has forced the FDA to fur­lough work­ers and hun­ker down around key tasks. But with cash run­ning out and their hands tied on gath­er­ing new fees, the agency is on the verge of see­ing its work on new drug ap­provals be­gin to grind to a halt. And a host of promi­nent health­care groups — in­clud­ing some well known sci­en­tif­ic or­ga­ni­za­tions — are warn­ing that the shut­down now threat­ens the na­tion’s ac­cess to cru­cial new ther­a­pies.

In a let­ter to Pres­i­dent Trump, Speak­er Nan­cy Pelosi and oth­er law­mak­ers on Tues­day, 46 ad­vo­ca­cy or­ga­ni­za­tions and pro­fes­sion­al so­ci­eties called for an end to the shut­down and asked that the FDA re­turn to full ca­pac­i­ty be­cause the health of Amer­i­cans is at stake.

“(W)e fear that this con­tin­ued shut­down not on­ly puts the cur­rent health and safe­ty of Amer­i­cans at risk, but has be­gun to put fu­ture sci­en­tif­ic dis­cov­ery and in­no­va­tion in jeop­ardy,” they wrote. “The on­go­ing gov­ern­ment shut­down forces the FDA to make dif­fi­cult choic­es re­gard­ing to which es­sen­tial func­tions its great­ly re­duced re­sources are di­rect­ed. These are de­ci­sions that nev­er should have to be made — the health and safe­ty of Amer­i­cans to­day should nev­er be weighed against the prospect of new life-sav­ing ther­a­pies for pa­tients…”

“While we ap­plaud Com­mis­sion­er Got­tlieb, FDA lead­er­ship, and ‘es­sen­tial staff’ for tru­ly hero­ic work to keep many as­pects of its mis­sion func­tion­ing, we fear that this con­tin­ued shut­down not on­ly puts the cur­rent health and safe­ty of Amer­i­cans at risk, but has be­gun to put fu­ture sci­en­tif­ic dis­cov­ery and in­no­va­tion in jeop­ardy.”

The group in­cludes AS­CO and the Na­tion­al Or­ga­ni­za­tion for Rare Dis­eases, which play a role in fo­cus­ing at­ten­tion on im­por­tant new sci­en­tif­ic de­vel­op­ments in their re­spec­tive fields.

Ex­perts sug­gest the FDA has rough­ly 2 to 3 months of fund­ing on the de­vice side. The drug side is less flush, with about a month of fund­ing left. Sub­mis­sions made pri­or to the shut­down on De­cem­ber 22 will be dealt with as usu­al, while sub­mis­sions made af­ter that date are placed in queue and will like­ly not be worked on un­til the shut­down is re­solved, ac­cord­ing to Jef­feries an­a­lysts, who added that if the shut­down con­tin­ues be­yond a month from now, the FDA will on­ly be able to fo­cus on es­sen­tial mat­ters such as food/prod­uct/man­u­fac­tur­ing safe­ty and pri­or­i­ty re­view.

Over the past few years, the FDA has grown in­creas­ing­ly pop­u­lar with bio­phar­ma com­pa­nies, which have en­joyed the most re­spon­sive agency they’ve ever known. The fo­cus un­der Scott Got­tlieb has been on ac­cel­er­at­ed ap­provals and rapid re­sponse to hur­ry along new drugs from es­tab­lished com­pa­nies. And all of that is be­ing jeop­ar­dized by the shut­down af­ter a pe­ri­od of climb­ing pro­duc­tiv­i­ty and record drug ap­provals.

If the shut­down con­tin­ues for the fore­see­able fu­ture, “the agency will have some al­go­rithm of how they go through the queue with drugs/agents with pri­or­i­ty re­view and/or oth­er high need tak­ing pri­or­i­ty…our es­ti­mate is a PDU­FA could get de­layed by per­haps the length of time from when funds dry up (next month) to when the gov­ern­ment is back open,” Jef­feries an­a­lysts said.

A sep­a­rate let­ter from more than 280 or­ga­ni­za­tions rep­re­sent­ing health, the en­vi­ron­ment, doc­tors and pa­tients al­so urged Pres­i­dent Trump last week to re­open the gov­ern­ment.

“Sev­er­al agen­cies’ abil­i­ty to pro­vide crit­i­cal ser­vices, rang­ing from food and en­vi­ron­men­tal risk in­spec­tions to health ser­vices, have al­ready been dras­ti­cal­ly re­duced or are threat­ened if the shut­down con­tin­ues. We fear a pro­longed shut­down will cause need­less suf­fer­ing and have long-last­ing health con­se­quences,” they wrote.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.

Jim Mellon [via YouTube]

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

Earlier this year, an executive from Juvenescence-backed AgeX predicted the field of longevity will eventually “dwarf the dotcom boom.” Greg Bailey, the UK-based anti-aging biotech’s CEO, certainly hopes so.

On Monday, Juvenescence completed its $100 million Series B round of financing. The company is backed by British billionaire Jim Mellon — who wrote his 400-page guide to investing in the field of longevity shortly after launching the company in 2017. Bailey, who served as a board director for seven years at Medivation before Pfizer swallowed the biotech for $14 billion, is joined by Declan Doogan, an industry veteran with stints at Pfizer $PFE and Amarin $AMRN.

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.